Winning Health(300253)2025-04-24 08:55Financial Performance - The company's operating revenue for Q1 2025 was ¥344,975,742.42, a decrease of 30.24% compared to ¥494,492,405.71 in the same period last year[5] - Net profit attributable to shareholders was ¥5,289,433.21, down 68.18% from ¥16,620,407.26 year-on-year[5] - Basic and diluted earnings per share were both ¥0.0024, a decline of 68.83% from ¥0.0077 in the same period last year[5] - The company reported a total revenue of 344.98 million yuan, a year-on-year decrease of 30.24%[16] - The net profit attributable to shareholders was 5.29 million yuan, down 68.18% year-on-year, while the net profit after deducting non-recurring gains and losses was 4.77 million yuan, a decrease of 45.06%[16] - Software and technology service revenue was 291.83 million yuan, down 18.08% year-on-year; hardware sales revenue was 21.47 million yuan, down 75.65%; and internet healthcare revenue was 31.68 million yuan, down 36.77%[16] - Net profit for the period was a loss of ¥3,345,001.28 compared to a profit of ¥6,494,450.04 in the previous period, indicating a significant downturn[26] Cash Flow and Financial Health - The net cash flow from operating activities improved by 76.31%, reaching -¥25,792,140.49 compared to -¥108,888,969.06 in the previous year[5] - The company’s operating cash flow increased by 76.31% year-on-year, indicating effective cost control and stable cash flow[16] - Operating cash flow for the period was negative at -25,792,140.49 CNY, an improvement from -108,888,969.06 CNY in the previous period, indicating a reduction in cash outflow[28] - Total cash inflow from operating activities was 601,807,057.72 CNY, slightly down from 603,515,100.58 CNY in the prior period[28] - Cash outflow from operating activities decreased to 627,599,198.21 CNY from 712,404,069.64 CNY, reflecting better cost management[28] - Cash received from investment recoveries increased to 3,000,000.00 CNY from 1,350,073.13 CNY, indicating better investment management[29] - The ending cash and cash equivalents balance rose to 1,276,220,650.49 CNY from 904,104,252.84 CNY, reflecting a strong liquidity position[29] Assets and Equity - Total assets at the end of the reporting period were ¥8,620,532,947.41, a decrease of 1.55% from ¥8,756,485,456.90 at the end of the previous year[5] - The company's total assets decreased to ¥8,620,532,947.41 from ¥8,756,485,456.90, a decline of approximately 1.6%[23] - The company's total equity attributable to shareholders increased by 1.14% to ¥6,029,735,350.20 from ¥5,961,679,015.97 at the end of the previous year[5] - The company's equity attributable to shareholders increased to ¥6,029,735,350.20 from ¥5,961,679,015.97, showing a growth of approximately 1.1%[23] Shareholder Information - The top 10 unrestricted shareholders collectively hold 423,802,370 shares, accounting for 19.16% of the total share capital[13] - The largest unrestricted shareholder is Shanghai Yunxin Venture Capital Co., Ltd., holding 95,987,348 shares[12] - Liu Ning and his spouse, along with four private equity products, collectively hold 140,627,616 shares, representing 6.36% of the total share capital[13] - The company has a total of 77,749,000 shares held by shareholders with over 5% ownership, which is 3.52% of the total share capital[13] - The company has not disclosed any relationships or agreements among other shareholders[13] - The total number of shares held by the top 10 shareholders participating in margin trading is not applicable[13] - The company has not reported any changes in the top 10 shareholders due to margin trading activities[13] - The company has a total of 34,919,000 shares held by various private equity funds through margin trading accounts[13] - The company has not issued any preferred shares, as indicated in the report[14] Investment and R&D - The company's investment income increased by 59.71% year-on-year, attributed to a decrease in losses from joint ventures[11] - The company reported a significant increase of over 200% in operating income from non-operating activities, mainly due to an increase in income not directly related to daily operations[11] - The company experienced a 131.06% increase in income tax compared to the previous year, driven by an increase in taxable income[11] - The company’s long-term equity investments decreased to ¥483,058,119.11 from ¥490,499,803.45, a decline of about 1%[22] - Research and development expenses decreased to ¥51,230,601.51 from ¥70,107,264.95, a reduction of about 27% year-over-year[25] - As of March 31, 2025, the company and its subsidiaries had obtained a total of 65 invention patents, 5 utility model patents, and 202 design patents[19] Other Information - The report does not provide any new product or technology development updates, market expansion, or acquisition strategies[12][14] - The company confirmed government subsidies totaling 20.90 million yuan, accounting for approximately 23.78% of the audited net profit attributable to shareholders for 2024[18] - The company issued 20,680,806 new shares through stock option exercises during the reporting period[18] - The company reported a credit impairment loss of ¥44,436,078.58, compared to ¥20,235,580.27 in the previous period, indicating an increase in credit risk[26] - The company’s cash flow report for the first quarter was not audited, which may affect the reliability of the reported figures[30]